Medium materiality6/10
Jefferies Reiterates Buy Rating on UroGen Pharma (URGN)
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Jefferies maintains Buy rating with a $56 target; current price $45.
- Jefferies maintains Buy; PT $56.
Key facts
- 01
Target: $56
- 02
Posted price: $45
- 03
Analyst firm: Jefferies
- 04
Analyst: Amin Makarem
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.